{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:09:12Z","timestamp":1792602552864,"version":"4.5.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T00:00:00Z","timestamp":1669766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ctrv.2022.102491","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T12:32:18Z","timestamp":1670329938000},"page":"102491","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":120,"special_numbering":"C","title":["Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts"],"prefix":"10.1016","volume":"112","author":[{"given":"Silvia","family":"Stacchiotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Roland","family":"D\u00fcrr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga-Marie","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Woertler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Trama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto","family":"Caraceni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Bajpai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo Giulio","family":"Baldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Bernthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjetil","family":"Boye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier-Martin","family":"Broto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Wu Tom","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Angelo","family":"Dei Tos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayesh","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Emhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Gronchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jendrik","family":"Hardes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Healey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Italiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin L.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Leithner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Loong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Mascard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Morosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Otten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Palmerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreyaskumar R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Reichardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Sangalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice M.","family":"Seddon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morena","family":"Shkcodra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Staals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Tap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"van de Rijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"van Langevelde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip M.M.","family":"Vanhoenacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisette","family":"Wiltink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel","family":"Van de Sande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2022.102491_b0005","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1080\/17453674.2017.1361126","article-title":"Higher incidence rates than previously known in tenosynovial giant cell tumours","volume":"88","author":"Mastboom","year":"2017","journal-title":"Acta Orthop"},{"key":"10.1016\/j.ctrv.2022.102491_b0010","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1097\/PAS.0b013e31802b86f8","article-title":"Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumour, rheumatoid arthtritis and other reactive synovitis","volume":"31","author":"Cupp","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2022.102491_b0015","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1093\/annonc\/mdy129","article-title":"Complete response to CSF1R inhibitor in a translocation variant of teno-synovial giant cell tumor without genomic alteration of the CSF1 gene","volume":"29","author":"Brahmi","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2022.102491_b0020","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/gcc.22807","article-title":"Detection of CSF1 rearrangements deleting the 3' UTR in tenosynovial giant cell tumors","volume":"59","author":"Ho","year":"2020","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.ctrv.2022.102491_b0025","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1002\/ijc.32421","article-title":"Massively parallel sequencing of tenosynovial giant cell tumors reveals novel CSF1 fusion transcripts and novel somatic CBL mutations","volume":"14","author":"Tsuda","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2022.102491_b0030","unstructured":"De Saint Aubain Somerhausen N, van de Rijn M. Tenosynovial Giant Cell Tumour, In: Antonescu CM et al., editors. World Health Organization (WHO) classification of soft tissue and bone tumours. Lyon: International Agency for Research on Cancer (IARC) 5th edition; 2020:133-6."},{"key":"10.1016\/j.ctrv.2022.102491_b0035","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/j.tripleo.2010.11.031","article-title":"Malignant pigmented villonodular synovitis of the temporomandibular joint with lung metastasis: a case report and review of the literature","volume":"111","author":"Yoon","year":"2011","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.ctrv.2022.102491_b0040","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13569-015-0030-2","article-title":"Metastasizing tenosynovial giant cell tumour, diffuse type\/pigmented villonodular synovitis","volume":"5","author":"Righi","year":"2015","journal-title":"Clin Sarcoma Res"},{"key":"10.1016\/j.ctrv.2022.102491_b0045","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1002\/cncr.33618","article-title":"Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities","volume":"127","author":"Stacchiotti","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2022.102491_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102455","article-title":"Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments","volume":"110","author":"Stacchiotti","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2022.102491_b0055","doi-asserted-by":"crossref","first-page":"e0121451","DOI":"10.1371\/journal.pone.0121451","article-title":"Pigmented villonodular synovitis: a retrospective multicenter study of 237 cases","volume":"10","author":"Xie","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2022.102491_b0060","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2014.11.001","article-title":"Tenosynovial giant cell tumour\/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors","volume":"51","author":"Palmerini","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2022.102491_b0065","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1016\/j.otsr.2016.11.002","article-title":"Localized and diffuse forms of tenosynovial giant cell tumor (formerly giant cell tumor of the tendon sheath and pigmented villonodular synovitis)","volume":"103","author":"Gouin","year":"2017","journal-title":"Orthop Traumatol Surg Res"},{"key":"10.1016\/j.ctrv.2022.102491_b0070","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/PAS.0b013e318158428f","article-title":"Malignant diffuse-type tenosynovial giant cell tumors: a series of 7 cases comparing with 24 benign lesions with review of the literature","volume":"32","author":"Li","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2022.102491_b0075","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41379-018-0129-0","article-title":"Malignant Tenosynovial Giant Cell Tumor: The True \u201cSynovial Sarcoma?\u201d a Clinicopathologic, Immunohistochemical, and Molecular Cytogenetic Study of 10 Cases, Supporting Origin from Synoviocytes","volume":"32","author":"Al-Ibraheemi","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ctrv.2022.102491_b0080","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1186\/s12885-018-5188-6","article-title":"Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy","volume":"18","author":"Nakayama","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2022.102491_b0085","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.3899\/jrheum.160816","article-title":"Tenosynovial Giant Cell Tumor: Incidence, Prevalence, Patient Characteristics, and Recurrence. A Registry-based Cohort Study in Denmark","volume":"44","author":"Ehrenstein","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ctrv.2022.102491_b0090","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1093\/rheumatology\/keu230","article-title":"Long-term follow-up results of primary and recurrent pigmented villonodular synovitis","volume":"53","author":"Verspoor","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.ctrv.2022.102491_b0095","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.semarthrit.2010.07.005","article-title":"Pigmented villonodular synovitis: a retrospective single-center study of 122 cases and review of the literature","volume":"40","author":"Ottaviani","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ctrv.2022.102491_b0100","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.jse.2019.05.007","article-title":"The surgical outcome and recurrence rate of tenosynovial giant cell tumor in the elbow: a literature review","volume":"28","author":"Al Farii","year":"2019","journal-title":"J Shoulder Elbow Surg"},{"key":"10.1016\/j.ctrv.2022.102491_b0105","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.suronc.2020.08.030","article-title":"The effect of Imatinib Mesylate in diffuse-type Tenosynovial Giant Cell Tumours on MR imaging and PET-CT","volume":"35","author":"Mastboom","year":"2020","journal-title":"Surg Oncol"},{"key":"10.1016\/j.ctrv.2022.102491_b0110","doi-asserted-by":"crossref","first-page":"233","DOI":"10.4103\/jpgm.JPGM_305_19","article-title":"Pigmented villonodular synovitis: four pediatric cases and brief review of literature","volume":"65","author":"Turkucar","year":"2019","journal-title":"J Postgrad Med"},{"key":"10.1016\/j.ctrv.2022.102491_b0115","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s00256-020-03694-4","article-title":"Limited usefulness of classic MR findings in the diagnosis of tenosynovial giant cell tumor","volume":"50","author":"Crim","year":"2021","journal-title":"Skeletal Radiol"},{"key":"10.1016\/j.ctrv.2022.102491_b0120","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10067-003-0827-x","article-title":"MRI features of pigmented villonodular synovitis (PVNS)","volume":"23","author":"Cheng","year":"2004","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ctrv.2022.102491_b0125","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00247-004-1261-1","article-title":"Pigmented villonodular synovitis: MR imaging in pediatric patients","volume":"34","author":"Eckhardt","year":"2004","journal-title":"Pediatr Radiol"},{"key":"10.1016\/j.ctrv.2022.102491_b0130","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2214\/ajr.181.2.1810539","article-title":"Localized nodular synovitis of the knee: MR imaging appearance and clinical correlates in 21 patients","volume":"181","author":"Huang","year":"2003","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.ctrv.2022.102491_b0135","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s003300050134","article-title":"Magnetic resonance imaging of localized giant cell tumour of the tendon sheath (MRI of localized GCTTS)","volume":"7","author":"De Beuckeleer","year":"1997","journal-title":"Eu Radiol"},{"key":"10.1016\/j.ctrv.2022.102491_b0140","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1007\/s00167-018-4942-2","article-title":"Distinct extra-articular invasion patterns of diffuse pigmented villonodular synovitis\/tenosynovial giant cell tumor in the knee joints","volume":"26","author":"Kim","year":"2018","journal-title":"Knee Surg Sports Traumatol Arthrosc"},{"key":"10.1016\/j.ctrv.2022.102491_b0145","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.suronc.2018.07.002","article-title":"Severity classification of Tenosynovial Giant Cell Tumours on MR imaging","volume":"27","author":"Mastboom","year":"2018","journal-title":"Surg Oncol"},{"key":"10.1016\/j.ctrv.2022.102491_b0150","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1007\/s00402-021-04242-y","article-title":"Outcomes of arthroscopic management for pigmented villonodular synovitis of the hip","volume":"142","author":"Tang","year":"2021","journal-title":"Arch Orthop Trauma Surg"},{"issue":"45","key":"10.1016\/j.ctrv.2022.102491_b0155","first-page":"228","article-title":"New response evaluation criteria in solid tumours: revised RECIST guidelines (version 1.1)","volume":"2009","author":"Eisenhauer","year":"1990","journal-title":"Eur J Cancer Oxf Engl"},{"key":"10.1016\/j.ctrv.2022.102491_b0160","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/his.13744","article-title":"Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee?","volume":"74","author":"Mastboom","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.ctrv.2022.102491_b0165","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S1470-2045(19)30100-7","article-title":"Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study","volume":"20","author":"Mastboom","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2022.102491_b0170","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/jcp.54.5.404","article-title":"Giant cell tumour of tendon sheath (localised nodular tenosynovitis): clinicopathological features of 71 cases","volume":"54","author":"Monaghan","year":"2001","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.ctrv.2022.102491_b0175","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/00000478-200004000-00002","article-title":"Diffuse-type giant cell tumor: clinicopathologic and immunohistochemical analysis of 50 cases with extraarticular disease","volume":"24","author":"Somerhausen","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2022.102491_b0180","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1148\/rg.285085134","article-title":"Pigmented villonodular synovitis: radiologic-pathologic correlation","volume":"28","author":"Murphey","year":"2008","journal-title":"Radiographics"},{"key":"10.1016\/j.ctrv.2022.102491_b0185","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1097\/PAS.0b013e3181a6d86f","article-title":"Clusterin is expressed in normal synoviocytes and in tenosynovial giant cell tumors of localized and diffuse types: diagnostic and histogenetic implications","volume":"33","author":"Boland","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2022.102491_b0190","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.path.2021.06.008","article-title":"Intra-Articular Tumors","volume":"14","author":"Sbaraglia","year":"2021","journal-title":"Surg Pathol Clin"},{"key":"10.1016\/j.ctrv.2022.102491_b0195","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/0046-8177(95)90226-0","article-title":"Giant cell tumor of tendon sheath and pigmented villonodular synovitis: immunophenotype suggests a synovial cell origin","volume":"26","author":"O'Connell","year":"1995","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ctrv.2022.102491_b0200","doi-asserted-by":"crossref","unstructured":"van IJzendoorn DGP, Matusiak M, Charville GW, et al. Interactions in CSF1-driven Tenosynovial Giant Cell Tumors. Clin Cancer Rev 2022;CCR-22-1898 doi: 10.1158\/1078-0432.CCR-22-1898.","DOI":"10.1101\/2022.06.01.494428"},{"key":"10.1016\/j.ctrv.2022.102491_b0205","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/gcc.20501","article-title":"Molecular identification of COL6A3-CSF1 fusion transcripts in tenosynovial giant cell tumors","volume":"47","author":"Moller","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.ctrv.2022.102491_b0210","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1411366","article-title":"Structure-Guided Blockade of CSF1R kinase in tenosynovial giant-cell tumor","volume":"373","author":"Tap","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2022.102491_b0215","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.annonc.2021.07.006","article-title":"ESMO Guidelines Committee, EURACAN and GENTURIS. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Gronchi","year":"2021","journal-title":"Ann Oncol"},{"issue":"e20","key":"10.1016\/j.ctrv.2022.102491_b0220","first-page":"00028","article-title":"Management of Tenosynovial Giant Cell Tumor: A Neoplastic and Inflammatory Disease","volume":"4","author":"Healey","year":"2020","journal-title":"J Am Acad Orthop Surg Glob Res Rev"},{"key":"10.1016\/j.ctrv.2022.102491_b0225","doi-asserted-by":"crossref","DOI":"10.1002\/jso.27067","article-title":"A prospective real-world study of the diffuse-type tenosynovial giant cell tumor patient journey: a 2-year observational analysis","author":"Bernthal","year":"2022","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ctrv.2022.102491_b0230","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13023-021-01820-6","article-title":"The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study","volume":"16","author":"Bernthal","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ctrv.2022.102491_b0235","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.2106\/JBJS.18.01147","article-title":"Surgical Treatment of Localized-Type Tenosynovial Giant Cell Tumors of Large Joints: a study based on a multicenter-pooled database of 31 international sarcoma centers","volume":"101","author":"Mastboom","year":"2019","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.ctrv.2022.102491_b0240","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.arthro.2020.01.059","article-title":"Mid-Term Results of Arthroscopic Synovectomy for Pigmented Villonodular Synovitis of the Hip","volume":"36","author":"Nazal","year":"2020","journal-title":"Arthroscopy"},{"key":"10.1016\/j.ctrv.2022.102491_b0245","doi-asserted-by":"crossref","first-page":"e0260795","DOI":"10.1371\/journal.pone.0260795","article-title":"Treatment, recurrence rates and follow-up of Tenosynovial Giant Cell Tumor (TGCT) of the foot and ankle-A systematic review and meta-analysis","volume":"16","author":"Siegel","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2022.102491_b0250","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s00167-014-3375-9","article-title":"Combined arthroscopic and open synovectomy for diffuse pigmented villonodular synovitis of the knee","volume":"24","author":"Mollon","year":"2016","journal-title":"Knee Surg Sports Traumatol Arthrosc"},{"key":"10.1016\/j.ctrv.2022.102491_b0255","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.knee.2017.03.011","article-title":"Pigmented villonodular synovitis of the knee: a retrospective analysis of 214 cases at a UK tertiary referral centre","volume":"24","author":"Patel","year":"2017","journal-title":"Knee"},{"key":"10.1016\/j.ctrv.2022.102491_b0260","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.arthro.2014.04.101","article-title":"Treatment of pigmented villonodular synovitis of the knee","volume":"30","author":"Auregan","year":"2014","journal-title":"Arthroscopy"},{"key":"10.1016\/j.ctrv.2022.102491_b0265","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.knee.2017.04.019","article-title":"Long-term outcome of knee arthroplasty in the setting of pigmented villonodular synovitis","volume":"24","author":"Houdek","year":"2017","journal-title":"Knee"},{"key":"10.1016\/j.ctrv.2022.102491_b0270","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.arth.2017.12.030","article-title":"Long-Term Outcome of Hip Arthroplasty in the Setting of Pigmented Villonodular Synovitis","volume":"33","author":"Tibbo","year":"2018","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.ctrv.2022.102491_b0275","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00402-018-3097-4","article-title":"The effects of radiosynoviorthesis in pigmented villonodular synovitis of the knee","volume":"139","author":"D\u00fcrr","year":"2019","journal-title":"Arch Orthop Trauma Surg"},{"key":"10.1016\/j.ctrv.2022.102491_b0280","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","article-title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial","volume":"394","author":"Tap","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2022.102491_b0285","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/cncr.26409","article-title":"Efficacy of imatinib mesylate for the treatment of locally advanced and\/or metastatic tenosynovial giant cell tumour\/pigmented villonodular synovitis","volume":"118","author":"Cassier","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2022.102491_b0290","doi-asserted-by":"crossref","first-page":"14551","DOI":"10.1038\/s41598-019-51211-y","article-title":"Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor","volume":"9","author":"Verspoor","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2022.102491_b0295","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S1470-2045(18)30143-8","article-title":"Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial","volume":"19","author":"Gelderblom","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2022.102491_b0300","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejca.2022.06.028","article-title":"Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours: Long-term follow-up of nilotinib in TGCT","volume":"173","author":"Spierenburg","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2022.102491_b0305","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s40265-019-01210-0","article-title":"Pexidartinib: first approval","volume":"79","author":"Lamb","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ctrv.2022.102491_b0310","doi-asserted-by":"crossref","first-page":"e863","DOI":"10.1002\/onco.13629","article-title":"Pexidartinib long-term hepatic safety profile in patients with tenosynovial giant cell tumors","volume":"26","author":"Lewis","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2022.102491_b0315","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S1470-2045(15)00132-1","article-title":"CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase I study","volume":"16","author":"Cassier","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2022.102491_b0320","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejca.2020.09.038","article-title":"Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour","volume":"141","author":"Cassier","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2022.102491_b0325","doi-asserted-by":"crossref","unstructured":"Sankhala KK, Blay JY, Ganjoo KN, et al. A phase I\/II dose escalation and expansion study of cabiralizumab (FPA-008), an anti-CSF1R antibody, in tenosynovial giant cell tumor (TGCT, diffuse pigmented villonodular synovitis D-PVNS). J Clin Oncol 2017 suppl; abstr 11078.","DOI":"10.1200\/JCO.2017.35.15_suppl.11078"},{"key":"10.1016\/j.ctrv.2022.102491_b0330","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1158\/1078-0432.CCR-21-2007","article-title":"Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT","volume":"28","author":"Tap","year":"2022","journal-title":"Clin Can Res"},{"key":"10.1016\/j.ctrv.2022.102491_b0335","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/cncr.33312","article-title":"Long-term outcomes of pexidartinib in tenosynovial giant cell tumors","volume":"127","author":"Gelderblom","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2022.102491_b0340","first-page":"S681","article-title":"Efficacy and safety of vimseltinib in tenosynovial giant cell tumour (TGCT): Phase II expansion","volume":"suppl_7","author":"Blay","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2022.102491_b0345","first-page":"S681","article-title":"The synovial and systemic pharmacokinetics and pharmacodynamics of intra-articular administration of the CSF1 receptor antibody AMB-05X in a phase II proof-of-concept trial in tenosynovial giant cell tumor","volume":"suppl_7","author":"Gelderblom","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2022.102491_b0350","doi-asserted-by":"crossref","unstructured":"van der Heijden L, Mastboom MJ, Dijkstra PD, van de Sande MA. Functional outcome and quality of life after the surgical treatment for diffuse-type giant-cell tumour around the knee: a retrospective analysis of 30 patients. Bone Joint J 2014; 96-B:1111-8.","DOI":"10.1302\/0301-620X.96B8.33608"},{"key":"10.1016\/j.ctrv.2022.102491_b0355","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.2196\/ijmr.9325","article-title":"The patient perspective on the impact of tenosynovial giant cell tumors on daily living: crowdsourcing study on physical function and quality of life","volume":"7","author":"Mastboom","year":"2018","journal-title":"Interact J Med Res"},{"key":"10.1016\/j.ctrv.2022.102491_b0360","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.clinthera.2018.03.001","article-title":"Burden of illness associated with tenosynovial giant cell tumors","volume":"40","author":"Burton","year":"2018","journal-title":"Clin Ther"},{"key":"10.1016\/j.ctrv.2022.102491_b0365","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1302\/0301-620X.101B3.BJJ-2018-0804.R1","article-title":"The effect of surgery in tenosynovial giant cell tumours as measured by patient-reported outcomes on quality of life and joint function","volume":"101","author":"Verspoor","year":"2019","journal-title":"Bone Joint J"},{"key":"10.1016\/j.ctrv.2022.102491_b0370","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s41687-020-00217-6","article-title":"Psychometric properties of a custom Patient-Reported Outcomes Measurement Information System (PROMIS) physical function short form and worst stiffness numeric rating scale in tenosynovial giant cell tumors","volume":"4","author":"Speck","year":"2020","journal-title":"J Patient Rep Outcomes"},{"key":"10.1016\/j.ctrv.2022.102491_b0375","doi-asserted-by":"crossref","first-page":"e588","DOI":"10.1016\/S1470-2045(18)30415-7","article-title":"Integration of oncology and palliative care: a Lancet Oncology Commission","volume":"19","author":"Kaasa","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2022.102491_b0380","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/S1470-2045(16)30577-0","article-title":"Referral criteria for outpatient specialty palliative cancer care: an international consensus","volume":"17","author":"Hui","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2022.102491_b0385","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/ejp.1736","article-title":"European clinical practice recommendations on opioids for chronic noncancer pain\u2013Part 1: role of opioids in the management of chronic noncancer pain","volume":"25","author":"H\u00e4user","year":"2021","journal-title":"Eur J Pain"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222001608?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222001608?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:27:21Z","timestamp":1759656441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737222001608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":77,"alternative-id":["S0305737222001608"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102491","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102491","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102491"}}